eftilagimod alpha,pembrolizumab
immutep,merck
['tacti-002', 'sclc', 'nsclc', 'eftilagimod', 'pembrolizumab', 'biomarker']
tacti-002: eftilagimod alpha (#efti; soluble lag-3) plus #pembrolizumab in 1st line nsclc unselected for pd-l1 presented by n=114
orr (by irecist)=38.6%
mpfs=6.9 months
any grade 5 trae=2.6% lag-3 is a relevant target. biomarkers to select pts needed. #asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM